STADA to invest $100M in Saudi Arabia manufacturing hub

STADA, a global healthcare company headquartered in Germany, announced it will invest more than €85 million ($100 million) to construct a pharmaceutical manufacturing facility in Saudi Arabia.

The site will be STADA’s first manufacturing facility in the Middle East and North Africa and will serve as a strategic supply hub for the broader region, according to the announcement. 

The 250,000-square-foot facility is reportedly designed to produce multi-technology solid dosage forms with an annual capacity of more than 300 million units at 85% utilization, supported by a 3,300-plus pallet warehouse and dedicated cold rooms for environmental control. According to the company, the site will be fully operational by 2030 and complement its existing network of 16 manufacturing facilities across Europe and Asia.

In its first five years of operation, the plant is expected to supply approximately 500 million cardiovascular medicine units, 175 million anticoagulant units and nearly 250 million type 2 diabetes treatments for patients in Saudi Arabia and the wider region. The facility will also produce central nervous system therapies and gastrointestinal treatments, according to the company.

STADA said the investment supports Saudi Arabia’s efforts to expand domestic pharmaceutical manufacturing capacity and reduce reliance on imports. The project is expected to create around 400 jobs.